Real-World Evidence of Patient Experience With Once-Daily Deutetrabenazine Extended-Release Tablets for Tardive Dyskinesia and Chorea in Huntington Disease in the United States
Background: Deutetrabenazine is approved by the United States Food and Drug Administration for treatment of tardive dyskinesia (TD) and chorea in Huntington disease (HD). This interim analysis (cut off: August 2, 2024), explored patient-reported ease of use, effectiveness, and satisfaction with once-daily (QD) deutetrabenazine extended-release tablets.
Methods: This non-interventional, prospective, cross-sectional, institutional review board–approved survey included adults with TD or HD-related chorea taking deutetrabenazine QD. Participants in Shared Solutions patient support program who completed/were due for their 12-week nurse outreach phone call were eligible for screening. Participants who consented received study materials by mail or email.
Results: Among 131 respondents (118 TD, 13 HD; mean age 59.1 years, 70% female, 94% White), 44% reported no prior TD/HD chorea medication. 74% reported that their extra movements were very much/much improved with deutetrabenazine QD; >76% strongly agreed/agreed that since starting deutetrabenazine QD, reduction in their extra movements has improved their comfort in social settings and emotional well-being. 57% and 53% strongly agreed/agreed that reduction in their extra movements has improved their overall physical health and work/school life, respectively. 98% reported it was very/somewhat easy to take deutetrabenazine QD. Most (95%) strongly agreed/agreed that they will continue taking deutetrabenazine QD; 87% reported satisfaction with deutetrabenazine QD.
Conclusion: Most participants reported overall satisfaction with deutetrabenazine QD, with the medication being easy to use and include in their daily routines. Most participants reported improvements in their extra movements since starting deutetrabenazine QD, which led to positive impacts on several quality-of-life domains.
